ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1414	National Cancer Institute	Html	en	Hot Flashes and Night Sweats (PDQ®)–Patient Version	Expert-reviewed information summary about causes and treatment of hot flashes and night sweats in cancer patients.	cancer treatment 0.577378 breast cancer growth 0.57462 PDQ Hot Flashes 0.643088 PDQ cancer information 0.710576 clinical trial search 0.554702 clinical trials 0.684197 body temperature 0.616838 health care providers 0.555017 cancer information summary 0.634163 severe hot flashes 0.621374 clinical trial 0.594616 breast cancer prevention 0.567917 PDQ health 0.569751 PDQ summaries 0.568709 patients 0.592891 cancer patients 0.574113 latest published information 0.55886 estrogen -like substances 0.556219 NCI’s PDQ 0.568469 NCI PDQ cancer 0.6094 cancer survivors 0.55389 hot flashes 0.920465 treatment 0.612089 night sweats 0.802654	estrogen replacement 0.579416 psychological interventions 0.568926 breast cancer recurrence 0.578473 Cancer Information Service 0.575801 PDQ Supportive 0.564083 estrogen replacement therapy 0.560222 treatment clinical trials 0.565907 National Cancer Institute 0.636027 nighttime hot flashes 0.618591 PDQ documents 0.563513 Palliative Care Editorial 0.58817 new treatment 0.567162 Cancer Care page 0.56849 PDQ database 0.566974 breast cancer 0.719649 Care Editorial Board 0.588937 PDQ summary 0.580639 prostate cancer 0.599276 cancer clinical trials 0.581073 high blood pressure 0.551027 cancer information summaries 0.580862 health professional versions 0.550098 comprehensive cancer information 0.58061 cancer 0.738565	CLICK HERE
1600	National Cancer Institute	Html	en	Nutrition in Cancer Care (PDQ®)–Patient Version	Expert-reviewed information summary about the causes and management of nutritional problems that occur in patients with cancer.	cancer treatment 0.815724 foods 0.591336 body 0.50774 PDQ cancer information 0.539768 general health 0.483553 mouth sores 0.564301 nutrition problems 0.511061 cancer information summary 0.514016 Cancer Care section 0.490312 enteral nutrition 0.493173 cancer care 0.499373 cancer patients 0.772982 weight loss 0.581589 dry mouth 0.559356 NCI PDQ cancer 0.489458 nutrition 0.675709 effects 0.559624 good nutrition 0.476052 nutrition therapy 0.671346 radiation therapy 0.583611 Advanced Cancer section 0.512145 nutrition support care 0.489001 cancer treatments 0.531014 parenteral nutrition support 0.491942 cancer prevention 0.486895	cancer cells 0.480334 Cancer Information Service 0.511605 palliative care 0.476957 nutrients 0.514961 certain foods 0.495203 parenteral nutrition 0.492581 National Cancer Institute 0.539267 advanced cancer 0.530168 white blood cell 0.522179 fight infection 0.479873 low white blood 0.494372 breast cancer 0.518198 cancer patients control 0.508745 health 0.485589 food 0.567108 PDQ summary 0.508916 Eat foods 0.503278 following nutrition problems 0.482655 mouth 0.591038 cancer information summaries 0.483904 comprehensive cancer information 0.47883 cancer 0.980934 information 0.558957 Cancer survivors 0.484253	CLICK HERE
1622	National Cancer Institute	Html	en	PC-SPES (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of PC-SPES as a treatment for prostate cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	AI prostate cancer 0.303125 herbal supplement PC-SPES 0.226052 androgen receptor 0.217805 United States 0.217375 AI human prostate 0.265687 tumor cell lines 0.239745 prostate cancer cell 0.651484 cell growth 0.337694 PC-SPES mixture 0.233921 human cancer cells 0.227728 cancer cell lines 0.814613 active agents 0.216957 cell cycle arrest 0.28032 human ovarian cancer 0.210983 PC-SPES 0.565565 metastatic prostate cancer 0.246109 human breast cancer 0.222738 prostate cancer model 0.251984 prostate specific gene 0.222494 PSA levels 0.422352 Prostate Cancer Treatment 0.30307 LNCaP prostate cancer 0.263951 human prostate LNCaP 0.252103 aggregate PC-SPES mixture 0.22369	prostate cancer cells 0.283954 cell cycle effects 0.221846 cell cycle 0.301026 Abstract 0.225583 colon cancer growth 0.213185 DU-145 prostate cancer 0.299116 prostate specific antigen 0.22926 prostate cancer patients 0.5128 PSA expression 0.28316 hormone-insensitive prostate cancer 0.250196 vitro 0.242733 vitro estrogenic activity. 0.21527 LNCaP cells 0.250769 prostate cancer 0.975741 effects 0.268243 pretreatment PSA levels 0.220575 Cancer Lett 0.216432 reduced PSA expression 0.210327 serum PSA levels 0.222831 human cancer cell 0.295651 Scutellaria baicalensis 0.227162 PC-SPES capsules 0.218201 human prostate cancer 0.330615	CLICK HERE
1686	National Cancer Institute	Html	en	Family Caregivers in Cancer (PDQ®)–Patient Version	Expert-reviewed information summary about the challenges faced by family caregivers of cancer patients. This summary focuses on typical caregiver roles and concerns, and helpful interventions for caregivers.	caregiver important information 0.22262 caregiver strain 0.371983 treatment 0.253353 family caregivers 0.362406 family caregiver changes 0.244372 Family Caregiver Cancer 0.223982 caregivers 0.69556 health care team 0.853882	caregiver assessment 0.244811 caregiver 0.956966 patient 0.749025 caregiver distress 0.215995 family caregiver 0.474179 caregiver role 0.201845 cancer 0.481346 information 0.329903	CLICK HERE
1729	National Cancer Institute	Html	en	Hyperthermia in Cancer Treatment	A fact sheet that defines hyperthermia (treating tumors with heat) and its side effects.	cancer treatment 0.403898 peritoneal cavity temperature 0.426528 External applicators 0.382217 whole-body hyperthermia 0.729094 van der Zee 0.371709 Clinical Radiation Oncology. 0.380706 tumor location 0.365525 regional hyperthermia 0.5725 hyperthermic peritoneal perfusion 0.490656 metastatic cancer 0.36336 Gibbs FA Jr 0.369277 normal tissues 0.422996 cancer therapy 0.407309 hyperthermia treatment 0.61506 bladder cancer 0.363102 Deep tissue approaches 0.386891 clinical trials 0.532546 DeVita VT Jr. 0.371357 interstitial hyperthermia 0.571391 hyperthermia 0.901227 tissue characteristics 0.386571 hot water blankets 0.375371 peritoneal cavity 0.431179 hyperthermia techniques 0.560349 radiation therapy 0.457463	high temperatures 0.42664 primary peritoneal mesothelioma 0.407141 local hyperthermia 0.597761 body cavity 0.386007 cancer cells 0.536875 anticancer drugs 0.424955 Cancer Information Service 0.393124 Libutti SK 0.372166 tumor size 0.36657 certain anticancer drugs 0.383187 B.C. Decker Inc. 0.373174 Samulski TV. Hyperthermia 0.573888 Numerous clinical trials 0.395138 Clinical Trials Information 0.383207 malignant peritoneal mesothelioma 0.399886 body tissue 0.392759 Regional perfusion techniques 0.40208 Bast RC Jr. 0.371129 stomach cancer 0.363295 tumor 0.394758 inserts small needles 0.373242 et al 0.437187 higher temperatures 0.384967 research studies 0.385011	CLICK HERE
1758	National Cancer Institute	Html	en	Radiation Therapy for Cancer	A fact sheet that defines the different types of radiation therapy and discusses scientific advances that improve the effectiveness of this treatment.	radiation beam-shaping devices 0.405709 cancer treatment 0.383308 radiation damage 0.388785 continuous low-dose radiation 0.400269 whole-brain radiation therapy 0.419192 clinical trials 0.384103 brachytherapy 0.350611 smaller radiation fields 0.402818 high-energy radiation 0.421756 radiation therapy kill 0.43549 neoadjuvant radiation 0.393279 high radiation doses 0.407974 radiation monitors 0.387758 exact radiation plan 0.408331 normal tissue 0.471558 Image-guided radiation therapy 0.421303 body radiation therapy 0.425833 radiation therapy machine 0.421108 radiation therapy 0.980996 radiation doses 0.416676 treatment 0.462098 cancer cells 0.462619 radiation exposure 0.418968 3-dimensional conformal radiation therapy 0.42971 radiation oncologists 0.38961	adjuvant radiation therapy 0.411117 treatment planning 0.350359 total radiation dose 0.44244 radiation energy 0.401543 standard external-beam radiation 0.404865 patient 0.382556 radiation source 0.404836 radiation side effects 0.390501 Stereotactic body radiation 0.413552 delivers radiation therapy 0.41809 palliative radiation therapy 0.444425 radiation delivery 0.401163 Intensity-modulated radiation therapy 0.422003 external-beam radiation therapy 0.67618 publications Radiation Therapy 0.411985 systemic radiation therapy 0.554464 radiation treatment 0.409027 traditional radiation therapy 0.410276 radiation sources 0.408845 electromagnetic radiation 0.398457 tumor 0.381132 intraoperative radiation therapy 0.411493 internal radiation therapy 0.476394 radiation therapy drugs 0.418615	CLICK HERE
1820	National Cancer Institute	Html	es	Tratamiento del rabdomiosarcoma infantil (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del rabdomiosarcoma infantil.	rhabdomyosarcoma patient 0.0299377 embryonal rhabdomyosarcoma with 0.0333796 Cancer Res Clin 0.0162353 results from 0.01769 prognostic factors 0.0264003 spindle cell rhabdomyosarcomas 0.019783 Tissue Sarcoma Study 0.0288157 Sin embargo 0.0245253 intergroup rhabdomyosarcoma studies 0.0596756 Rhabdomyosarcoma With Low-Risk 0.0321933 molecularly indistinguishable from 0.0208039 metastatic rhabdomyosarcomas 0.0266236 Intergroup Rhabdomyosarcoma Committee 0.0168747 Group Soft Tissue 0.018066 Alveolar Rhabdomyosarcoma With 0.0442707 lymph node biopsy 0.0162009 patients with nonmetastatic 0.037603 patients with 0.0939786 Rhabdomyosarcoma Study Group 0.0347209 oncology group report 0.0309001 soft tissue sarcoma 0.90779 Intergroup Rhabdomyosarcoma Study 0.199615 Pappo AS 0.0234049 intergroup rhabdomyosarcoma study-iv 0.0268353 fusion status 0.031797	ganglio linfático centinela 0.0180392 pediatric rhabdomyosarcoma 0.0285282 Ferrari A 0.032325 Pediatr Blood Cancer 0.298233 report from 0.448539 National Cancer Institute 0.0204895 rhabdomyosarcoma with 0.0598247 With Low-Risk Clinical 0.0191066 características histológicas 0.572518 Cooperative Soft Tissue 0.0269183 Med Genet 0.0241399 Pediatr Surg 0.0232296 Pediatr Hematol Oncol 0.0201008 Clin Oncol 0.467523 Med Pediatr Oncol 0.0214986 rhabdomyosarcoma is clinically 0.0229347 tissue sarcoma committee 0.33808 tumores embrionarios 0.0364557 alveolar rhabdomyosarcoma 0.101176 children's oncology group 0.895264 rabdomiosarcoma embrionario vs 0.0329873 rabdomiosarcoma botrioide 0.0236888 intergroup rhabdomyosarcoma 0.352028 embryonal rhabdomyosarcoma 0.0962874	CLICK HERE
1945	National Cancer Institute	Html	es	Efectos tardíos del tratamiento anticanceroso en la niñez (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de los problemas de salud que aparecen una vez que termina el tratamiento del cáncer.	cancer statistics 0.312893 among adult survivors 0.309342 health insurance 0.30576 childhood leukemia survivors 0.314627 Marrow Transplant Survivor 0.306695 largo plazo 0.353459 Cancer Survivor cohort 0.310798 CA Cancer 0.308516 group long-term follow-up 0.307764 mortality among 5-year 0.309974 health conditions 0.3067 young adult cancers 0.387348 late mortality 0.309117 Ness KK 0.312945 among childhood cancer 0.329959 adult survivors 0.341543 Hudson MM 0.322937 among survivors 0.313213 British Childhood Cancer 0.315849 utilization among long-term 0.306183 childhood cancer 0.973475 cancer survivor study 0.608871 late effects 0.312383 SEER Cancer Statistics 0.308306 long-term survivors 0.338777	health care utilization 0.307102 Survivor Study cohort 0.310239 chronic health conditions 0.305835 among adolescent survivors 0.308292 Care Cancer 0.309376 among 5-year survivors 0.328567 Pediatr Blood Cancer 0.42011 oncology group long-term 0.310223 adolescent cancers 0.313982 efectos tardíos 0.375703 survivors research program 0.306998 report from 0.396085 National Cancer Institute 0.308232 Oeffinger KC 0.306859 health care 0.314251 mortality among survivors 0.308816 Clin Oncol 0.375569 childhood cancer survivor 0.872407 medical care 0.307228 among long-term survivors 0.315379 late mortality among 0.306982 long-term follow-up guidelines 0.320022 Outcomes Among Childhood 0.309917 children's oncology group 0.433388	CLICK HERE
3876	National Cancer Institute	Html	en	The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)	Apply for the NCI F99/K00 Award that helps late-stage doctoral candidates finish their training and then transition into cancer-focused research positions.	K00 phase institution 0.388613 applicant institution 0.265884 Research Doctoral candidates 0.275389 Funding Opportunity Announcement 0.903132 research supplies 0.244496 Career Development Award 0.350987 k00 award 0.331719 Ph.D. dissertation requirements 0.237088 phase institutional representative 0.335728 project award period 0.253621 indirect costs 0.425626 NCI F99/K00 Predoc 0.307817 Institutional Allowance 0.281782 Career Development Support 0.249362 Research Career Development 0.347168 k00 phase 0.762118 Research Plan section 0.261319 career development skills 0.241364 health-related Ph.D. program 0.243519 F99 primary sponsor 0.23706 Research Service Award 0.312163 Individual Research Career 0.265006 mandatory NCI-sponsored conference 0.307767 Opportunity Announcement instructions 0.260896 career development research 0.317687	dissertation research project 0.396866 Ph.D. degree program 0.256222 valid U.S. visas 0.237157 Postdoctoral Fellow Transition 0.248842 Application Guide 0.311615 NCI Predoctoral 0.237727 F99 phase 0.471921 dissertation research training 0.299174 program staff 0.238571 Program Staff Contact 0.236142 Research Strategy 0.247855 F99/K00 Award 0.359733 F99 grant mechanism 0.235643 assigned NCI Program 0.270275 Development Award Supplemental 0.254853 F99 award 0.269956 fringe benefits 0.272186 valid U.S. visa 0.254123 career development 0.562023 Research Plan Sections 0.252481 Fellowship Applicant Section 0.257658 F99/K00 Award application 0.300758 health-related research field 0.279872 Postdoctoral Research Direction 0.273719	CLICK HERE
15846	National Cancer Institute	Html	en	RAS Biochemistry and Biophysics	This RAS Biochemistry and Biophysics lab investigates signaling by RAS proteins, which is regulated by the interactions with substrates, protein partners, and membranes.	cell membranes 0.473685 Nuclear Magnetic Resonance 0.585708 Biophysics Group team 0.636374 mutant RAS 0.650163 KRAS proteins 0.677168 nanodiscs 0.374828 cancer deaths 0.469996 fully modified KRAS 0.804703 different cancers 0.503399 Washington University 0.469252 analytical ultracentrifugation 0.487353 protein-nanodisc complexes 0.475228 atomic levels 0.48075 stephena@mail.nih.gov 0.45777 Ridge National Laboratory 0.591017 Rodolfo Ghirlando 0.472711 artificial lipid bilayers 0.682865 KRAS4b protein 0.638588 sensitive techniques 0.481762 Carla Mattos 0.458864 California 0.350663 Northeastern University 0.475122 RAS proteins 0.703869 neutron scattering 0.468073 RAS Biochemistry 0.737959	different KRAS 0.64483 different lipid compositions 0.713219 Chris Stanley 0.450409 fully modified KRAS4b 0.914598 Jay Groves 0.463932 interactions 0.440981 intrinsic hydrolysis rates 0.625326 numerous interacting partner 0.64654 inner plasma membrane 0.635847 Marco Tonelli 0.478206 surrogate 0.33572 St. Louis 0.448878 Digestive Kidney Dieases 0.603479 National Institute 0.589812 Paul Henderson 0.462542 single molecule analysis 0.605131 different mutant proteins 0.699255 dozen different mutants 0.686498 biophysical assays 0.484191 binding affinities 0.477155 Steve Sligar 0.461855 biophysics group 0.812528 major oncogenic mutants 0.687098 KRAS account 0.631848	CLICK HERE